Restricted accessResearch articleFirst published online 2018-02
Pulmonary Drug Delivery Following Continuous Vibrating Mesh Nebulization and Inspiratory Synchronized Vibrating Mesh Nebulization During Noninvasive Ventilation in Healthy Volunteers
A breath-synchronized nebulization option that could potentially improve drug delivery during noninvasive positive pressure ventilation (NIPPV) is currently not available on single-limb circuit bilevel ventilators. The aim of this study was to compare urinary excretion of amikacin following aerosol delivery with a vibrating mesh nebulizer coupled to a single-limb circuit bilevel ventilator, using conventional continuous (Conti-Neb) and experimental inspiratory synchronized (Inspi-Neb) nebulization modes.
Materials and Methods:
A crossover clinical trial involving 6 noninvasive ventilated healthy volunteers (mean age of 32.3 ± 9.5 y) randomly assigned to both vibrating mesh nebulization modes was conducted: Inspi-Neb delivered aerosol during only the whole inspiratory phase, whereas Conti-Neb delivered aerosol continuously. All subjects inhaled amikacin solution (500 mg/4 mL) during NIPPV using a single-limb bilevel ventilator (inspiratory positive airway pressure: 12 cm H2O, and expiratory positive airway pressure: 5 cm H2O). Pulmonary drug delivery of amikacin following both nebulization modes was compared by urinary excretion of drug for 24 hours post-inhalation.
Results:
The total daily amount of amikacin excreted in the urine was significantly higher with Inspi-Neb (median: 44.72 mg; interquartile range [IQR]: 40.50–65.13) than with Conti-Neb (median: 40.07 mg; IQR: 31.00–43.73), (p = 0.02). The elimination rate constant of amikacin (indirect measure of the depth of drug penetration into the lungs) was significantly higher with Inspi-Neb (median: 0.137; IQR: 0.113–0.146) than with Conti-Neb (median: 0.116; IQR: 0.105–0.130), (p = 0.02). However, the mean pulmonary drug delivery rate, expressed as the ratio between total daily urinary amount of amikacin and nebulization time, was significantly higher with Conti-Neb (2.03 mg/min) than with Inspi-Neb (1.09 mg/min) (p < 0.01).
Conclusions:
During NIPPV with a single-limb circuit bilevel ventilator, the use of inspiratory synchronized vibrating mesh nebulization may improve pulmonary drug delivery compared with conventional continuous vibrating mesh nebulization.
Get full access to this article
View all access options for this article.
References
1.
EhrmannS, Roche-CampoF, Bodet-ContentinL, RazaziK, DugernierJ, Trenado-AlvarezJ, DonzeauA, VermeulenF, ThevozD, PapanikolaouM, EdelsonA, Leon YoshidoH, PiquilloudL, LakhalK, LopesC, VicentC, DesachyA, Apiou-SbirleaG, IsabeyD, BrochardL, Reva Research Network; AT@ICU Study Group: Aerosol therapy in intensive and intermediate care units: Prospective observation of 2808 critically ill patients. Intensive Care Med. 2016; 42:192–201.
2.
GuerinC, FassierT, BayleF, LemassonS, and RichardJC: Inhaled bronchodilator administration during mechanical ventilation: How to optimize it, and for which clinical benefit?. J Aerosol Med Pulm Drug Deliv. 2008; 21:85–96.
3.
HessDR: Aerosol therapy during noninvasive ventilation or high-flow nasal cannula. Respir Care. 2015; 60:880–891; discussion 891–883.
4.
Galindo-FilhoVC, RamosME, RattesCS, BarbosaAK, BrandaoDC, BrandaoSC, FinkJB, and de AndradeAD: Radioaerosol pulmonary deposition using mesh and jet nebulizers during noninvasive ventilation in healthy subjects. Respir Care. 2015; 60:1238–1246.
5.
BrandaoDC, LimaVM, FilhoVG, SilvaTS, CamposTF, DeanE, and de AndradeAD: Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma. J Asthma. 2009; 46:356–361.
6.
FaurouxB, IttiE, PigeotJ, IsabeyD, MeignanM, FerryG, LofasoF, WillemotJM, ClementA, and HarfA: Optimization of aerosol deposition by pressure support in children with cystic fibrosis: An experimental and clinical study. Am J Respir Crit Care Med. 2000; 162:2265–2271.
7.
Galindo-FilhoVC, BrandaoDC, Ferreira RdeC, MenezesMJ, Almeida-FilhoP, ParreiraVF, SilvaTN, Rodrigues-Machado MdaG, DeanE, and Dornelas de AndradeA: Noninvasive ventilation coupled with nebulization during asthma crises: A randomized controlled trial. Respir Care. 2013; 58:241–249.
8.
MaccariJG, TeixeiraC, SaviA, de OliveiraRP, MachadoAS, ToniettoTF, LudwigE, TeixeiraPJ, and KnorstMM: Nebulization during spontaneous breathing, CPAP, and bi-level positive-pressure ventilation: A randomized analysis of pulmonary radioaerosol deposition. Respir Care. 2014; 59:479–484.
9.
ChatburnRL, and McPeckM: A new system for understanding nebulizer performance. Respir Care. 2007; 52:1037–1050.
10.
DhandR: New frontiers in aerosol delivery during mechanical ventilation. Respir Care. 2004; 49:666–677.
11.
HarveyCJ, O'DohertyMJ, PageCJ, ThomasSH, NunanTO, and TreacherDF: Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur Respir J. 1997; 10:905–909.
12.
AbdelrahimME, PlantP, and ChrystynH: In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol. 2010; 62:966–972.
13.
McPeckM: Improved aerosol drug delivery with an electronic mesh nebulizer during non-invasive ventilation. (Abstract) Presented at the Amercican Thoracic Society 2012 International Conference, San Francisco, CA, May 18–23, 2012. Am J Respir Crit Care Med. 2012; 185:A3136.
14.
DaiB, KangJ, SunLF, TanW, and ZhaoHW: Influence of exhalation valve and nebulizer position on albuterol delivery during noninvasive positive pressure ventilation. J Aerosol Med Pulm Drug Deliv. 2014; 27:125–132.
15.
DhandR: Aerosol therapy in patients receiving noninvasive positive pressure ventilation. J Aerosol Med Pulm Drug Deliv. 2012; 25:63–78.
16.
CalvertLD, JacksonJM, WhiteJA, BarryPW, KinnearWJ, and O'CallaghanC: Enhanced delivery of nebulised salbutamol during non-invasive ventilation. J Pharm Pharmacol. 2006; 58:1553–1557.
17.
ChatmongkolchartS, SchettinoGP, DillmanC, KacmarekRM, and HessDR: In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: Effect of ventilator settings and nebulizer position. Crit Care Med. 2002; 30:2515–2519.
18.
MichotteJB, JossenE, RoeselerJ, LiistroG, and ReychlerG: In vitro comparison of five nebulizers during noninvasive ventilation: Analysis of inhaled and lost doses. J Aerosol Med Pulm Drug Deliv. 2014; 27:430–440.
19.
PrinceIR, RabbettsI, and DenyerJ: In vitro assessment of continuous, breath-actuated and Adaptive Aerosol Delivery (AAD®) for the delivery of aerosol into noninvasive ventilation. J Aerosol Med. 2007; 20:365–392.
20.
HessDR: The mask for noninvasive ventilation: Principles of design and effects on aerosol delivery. J Aerosol Med. 2007; 20Suppl 1:S85–S98; discussion S98–S89.
21.
MichotteJB, StaderiniE, Le PennecD, DugernierJ, RusuR, RoeselerJ, VecellioL, LiistroG, and ReychlerG: In vitro comparison of a vibrating mesh nebulizer operating in inspiratory synchronized and continuous nebulization modes during noninvasive ventilation. J Aerosol Med Pulm Drug Deliv. 2016; 29:328–336.
22.
NewmanSP: How well do in vitro particle size measurements predict drug delivery in vivo?. J Aerosol Med. 1998; 11Suppl 1:S97–S104.
23.
AriA, and FinkJB: Factors affecting bronchodilator delivery in mechanically ventilated adults. Nurs Crit Care. 2010; 15:192–203.
24.
AriA, FinkJB, and DhandR: Inhalation therapy in patients receiving mechanical ventilation: An update. J Aerosol Med Pulm Drug Deliv. 2012; 25:319–332.
25.
BranconnierMP, and HessDR: Albuterol delivery during noninvasive ventilation. Respir Care. 2005; 50:1649–1653.
26.
DequinPF, FaurissonF, LemarieE, DelatourF, MarchandS, ValatC, BoissinotE, de GiallulyC, and DiotP: Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J. 2001; 18:316–322.
27.
ReychlerG, LealT, RoeselerJ, ThysF, DelvauN, and LiistroG: Effect of continuous positive airway pressure combined to nebulization on lung deposition measured by urinary excretion of amikacin. Respir Med. 2007; 101:2051–2055.
28.
MoraineJJ, TruflandierK, VandenbergenN, BerreJ, MelotC, and VincentJL: Placement of the nebulizer before the humidifier during mechanical ventilation: Effect on aerosol delivery. Heart Lung. 2009; 38:435–439.
29.
AbdelrahimME, PlantPK, and ChrystynH: The relative lung and systemic bioavailability of terbutaline following nebulisation in non-invasively ventilated patients. Int J Pharm. 2011; 420:313–318.
30.
EhrmannS, MercierE, VecellioL, TernantD, PaintaudG, and DequinPF: Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med. 2008; 34:755–762.
31.
MarikP, HoganJ, and KrikorianJ: A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Chest. 1999; 115:1653–1657.
32.
MillerMR, HankinsonJ, BrusascoV, BurgosF, CasaburiR, CoatesA, CrapoR, EnrightP, van der GrintenCP, GustafssonP, JensenR, JohnsonDC, MacIntyreN, McKayR, NavajasD, PedersenOF, PellegrinoR, ViegiG, WangerJ, and ForceAET: Standardisation of spirometry. Eur Respir J. 2005; 26:319–338.
33.
FrancaEE, Dornelas de AndradeAF, CabralG, Almeida FilhoP, SilvaKC, Galindo FilhoVC, MarinhoPE, LemosA, and ParreiraVF: Nebulization associated with bi-level noninvasive ventilation: Analysis of pulmonary radioaerosol deposition. Respir Med. 2006; 100:721–728.
34.
ReychlerG, KeyeuxA, CremersC, VeriterC, RodensteinDO, and LiistroG: Comparison of lung deposition in two types of nebulization: Intrapulmonary percussive ventilation vs jet nebulization. Chest. 2004; 125:502–508.
35.
XiJ, SiX, ZhouY, KimJ, and BerlinskiA: Growth of nasal and laryngeal airways in children: Implications in breathing and inhaled aerosol dynamics. Respir Care. 2014; 59:263–273.
36.
NealeMG, BrownK, HodderRW, and AutyRM: The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol. 1986; 22:373–382.
37.
NoordzijM, TripepiG, DekkerFW, ZoccaliC, TanckMW, and JagerKJ: Sample size calculations: Basic principles and common pitfalls. Nephrol Dial Transplant. 2010; 25:1388–1393.
38.
BassettiM, LuytCE, NicolauDP, and PuginJ: Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016; 6:35.
39.
MillerDD, AminMM, PalmerLB, ShahAR, and SmaldoneGC: Aerosol delivery and modern mechanical ventilation: In vitro/in vivo evaluation. Am J Respir Crit Care Med. 2003; 168:1205–1209.
40.
GhazanfariT, ElhissiAM, DingZ, and TaylorKM: The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharm. 2007; 339:103–111.
41.
MacLoughlinRJ, HigginsBD, LaffeyJG, and O'BrienT: Optimized aerosol delivery to a mechanically ventilated rodent. J Aerosol Med Pulm Drug Deliv. 2009; 22:323–332.
42.
LinHL, WanGH, ChenYH, FinkJB, LiuWQ, and LiuKY: Influence of nebulizer type with different pediatric aerosol masks on drug deposition in a model of a spontaneously breathing small child. Respir Care. 2012; 57:1894–1900.
43.
ReychlerG, AubriotAS, DepoortereV, JamarF, and LiistroG: Effect of drug targeting nebulization on lung deposition: A randomized crossover scintigraphic comparison between central and peripheral delivery. Respir Care. 2014; 59:1501–1507.
44.
EhrmannS, LyazidiA, LouisB, IsabeyD, Le PennecD, BrochardL, and Apiou-SbirleaG: Ventilator-integrated jet nebulization systems: Tidal volume control and efficiency of synchronization. Respir Care. 2014; 59:1508–1516.
45.
LongestPW, AzimiM, and HindleM: Optimal delivery of aerosols to infants during mechanical ventilation. J Aerosol Med Pulm Drug Deliv. 2014; 27:371–385.
46.
LinHL, FinkJB, ZhouY, and ChengYS: Influence of moisture accumulation in inline spacer on delivery of aerosol using metered-dose inhaler during mechanical ventilation. Respir Care. 2009; 54:1336–1341.
47.
WalengaRL, TianG, HindleM, YelvertonJ, DodsonK, and LongestPW: Variability in nose-to-lung aerosol delivery. J Aerosol Sci. 2014; 78:11–29.
48.
FinkJ, and AriA: Aerosol delivery to intubated patients. Expert Opin Drug Deliv. 2013; 10:1077–1093.
49.
BeringerPM, OwensH, NguyenA, BenitezD, RaoA, and D'ArgenioDZ: Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012; 56:70–74.
50.
PelkonenAS, NikanderK, and TurpeinenM: Jet nebulization of budesonide suspension into a neonatal ventilator circuit: Synchronized versus continuous nebulizer flow. Pediatr Pulmonol. 1997; 24:282–286.
51.
WanGH, LinHL, FinkJB, ChenYH, WangWJ, ChiuYC, KaoYY, and LiuCJ: In vitro evaluation of aerosol delivery by different nebulization modes in pediatric and adult mechanical ventilators. Respir Care. 2014; 59:1494–1500.
ManthousCA, HallJB, SchmidtGA, and WoodLD: Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients. Am Rev Respir Dis. 1993; 148:1567–1570.
54.
BennettWD, ZemanKL, and KimC: Variability of fine particle deposition in healthy adults: Effect of age and gender. Am J Respir Crit Care Med. 1996; 153:1641–1647.
55.
FerronGA: Aerosol properties and lung deposition. Eur Respir J. 1994; 7:1392–1394.
56.
DhandR: Aerosol delivery during mechanical ventilation: From basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008; 21:45–60.
57.
DhandR, and MercierE: Effective inhaled drug administration to mechanically ventilated patients. Expert Opin Drug Deliv. 2007; 4:47–61.
58.
BransonRD, and GentileMA: Is humidification always necessary during noninvasive ventilation in the hospital?. Respir Care. 2010; 55:209–216; discussion 216.
HessD, FisherD, WilliamsP, PoolerS, and KacmarekRM: Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest. 1996; 110:498–505.
61.
GowdaAA, CucciaAD, and SmaldoneGC: Reliability of vibrating mesh technology. Respir Care. 2017; 62:65–69.
62.
RomeoVD, deMeirelesJ, SilenoAP, PimplaskarHK, and BehlCR: Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev. 1998; 29:89–116.
63.
O'HaganDT, CritchleyH, FarrajNF, FisherAN, JohansenBR, DavisSS, and IllumL: Nasal absorption enhancers for biosynthetic human growth hormone in rats. Pharm Res. 1990; 7:772–776.
64.
AguRU, JorissenM, WillemsT, Van den MooterG, KingetR, and AugustijnsP: Effects of pharmaceutical compounds on ciliary beating in human nasal epithelial cells: A comparative study of cell culture models. Pharm Res. 1999; 16:1380–1385.
65.
MerkusFW, VerhoefJC, SchipperNG, and MarttinE: Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998; 29:13–38.
66.
PassaliD, and Bianchini CiampoliM: Normal values of mucociliary transport time in young subjects. Int J Pediatr Otorhinolaryngol. 1985; 9:151–156.
